Share Incentive Plan and PDMR Dealings

RNS Number : 0122O

hVIVO plc

24 January 2019

 

HVIVO PLC

("hVIVO" or the "Company")

Share Incentive Plan and PDMR Dealings

London, UK, 24 January 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that as part of the Company's commitment to encouraging all employees to be shareholders in the business, a total of 1,689,258 Ordinary Shares of 5 pence each (the "New Ordinary Shares") have been granted to employees pursuant to a new employee share incentive plan introduced by hVIVO on 21 January 2019 (the "Share Incentive Plan").

A total of 138 employees were found eligible and applied for the Share Incentive Plan and have been granted 12,241 free Ordinary Shares each representing approximately £3,600 at the purchase price. The free shares were awarded on 21 January 2019 and are subject to a 3 year forfeiture period.

Application has been made to AIM for the admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, and Admission is expected to occur on 25 January 2019.

Following Admission, the total number of ordinary shares with voting rights in issue will be 82,296,965 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Dr Trevor Phillips (Executive Chairman), Tim Sharpington (COO, PDMR) and Shelley Fraser (Finance Director, PDMR) have been allotted 12,241 shares each, see below for further details.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Trevor Phillips
2	Reason for the notification
a)	Position/ status	Executive Chairman
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Award of ordinary shares pursuant to Share Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Trevor Phillips 29.41p 12,241
e)	Aggregated information - Aggregated volume - Price - Aggregated total	12,241 29.41p £3,600
f)	Date of the transaction	21 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Tim Sharpington
2	Reason for the notification
a)	Position/ status	COO, PDMR
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Award of ordinary shares pursuant to Share Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Tim Sharpington 29.41p 12,241
e)	Aggregated information - Aggregated volume - Price - Aggregated total	12,241 29.41p £3,600
f)	Date of the transaction	21 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Shelley Fraser
2	Reason for the notification
a)	Position/ status	Finance Director, PDMR
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Award of ordinary shares pursuant to Share Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Shelley Fraser 29.41p 12,241
e)	Aggregated information - Aggregated volume - Price - Aggregated total	12,241 29.41p £3,600
f)	Date of the transaction	21 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	[phone]
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	[phone]

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

 

END

 

 

DSHPGUMUGUPBGUC